Jigsawdio Multisensory Puzzle Platform: Jigsawdio is a personalized multisensory puzzle platform that combines transparent physical puzzle pieces with images, stories, and audio presented through an iPad. Participants will complete two approximately 30- to 40-minute Jigsawdio sessions per week for six weeks, for a total of 12 sessions.
Standard Jigsaw Puzzle Activity: Participants will complete two approximately 30- to 40-minute standard jigsaw puzzle sessions per week for six weeks, for a total of 12 sessions. Commercially available dementia-friendly puzzles will be used as the comparison activity.
Study summary
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia. Approximately 80 participants will be randomly assigned to either the Jigsawdio group or a control group using standard dementia-friendly jigsaw puzzles. Both groups will complete two 30- to 40-minute puzzle sessions per week for six weeks, for a total of 12 sessions.
Jigsawdio combines transparent physical puzzle pieces with personalized images, stories, and audio presented through an iPad. The study will compare changes in depression, anxiety, quality of life, cognition, engagement, satisfaction, and program feasibility. Assessments will be completed at baseline, after the six-week program, and at a 12-week follow-up. Information may also be collected from participants' caregivers or informants.
Eligibility
Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age: 60 years or older.
2. Able to communicate fluently in English.
3. Mild cognitive impairment or mild dementia based on an existing diagnosis or study screening procedures.
4. Has an informant and a puzzle creator who know the participant and are willing to participate in the study; the same person may serve in both roles.
Exclusion Criteria:
1. Severe uncorrected visual or hearing impairment that would prevent puzzle use.
2. Severe motor impairment that would prevent puzzle use.
3. Concurrent participation in a similar program or Alzheimer's disease intervention study.
4. Current hospice care or terminal illness.
5. Plans to relocate within three months after the baseline assessment.
6. History of a serious mental illness, such as bipolar disorder or schizophrenia, that would interfere with study participation.
7. Unable to provide informed consent and no legally authorized representative is available
Primary outcome measure(s)
Change in Quality of Life Measured by the Quality of Life in Alzheimer's Disease Scale — Baseline, Week 6, and Week 12 Quality of life will be measured using the Quality of Life in Alzheimer's Disease scale (QoL-AD). Total scores range from 13 to 52, with higher scores indicating better quality of life.
Change in Depressive Symptoms Measured by the Geriatric Depression Scale-15 — Baseline, Week 6, and Week 12 Depressive symptoms will be measured using the 15-item Geriatric Depression Scale (GDS-15). Total scores range from 0 to 15, with higher scores indicating greater depressive symptoms.
Change in Anxiety Symptoms Measured by the Generalized Anxiety Disorder-7 — Baseline, Week 6, and Week 12 Anxiety symptoms will be measured using the 7-item Generalized Anxiety Disorder scale (GAD-7). Total scores range from 0 to 21, with higher scores indicating greater anxiety symptoms.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.